Search research articles
Contact Us
Filters
Showing results (41-50 of 70) with videos related to
Page
of 7
Sort By:
Annals of the Rheumatic Diseases
|
April 22, 2016
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, et al.
The Journal of Dermatology
|
October 22, 2019
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2
Kristian Reich, Michael Song, Shu Li, et al.
Arthritis Care & Research
|
August 3, 2016
Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis
Proton Rahman, Lluis Puig, Alice B Gottlieb, et al.
The Journal of Rheumatology
|
April 3, 2019
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials
Iain B McInnes, Lluís Puig, Alice B Gottlieb, et al.
The Journal of Investigative Dermatology
|
June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
Kenneth B Gordon, April W Armstrong, Peter Foley, et al.
Arthritis Care & Research
|
June 23, 2015
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial
Arthur Kavanaugh, Lluís Puig, Alice B Gottlieb, et al.
Annals of the Rheumatic Diseases
|
February 21, 2014
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
Arthur Kavanaugh, Christopher Ritchlin, Proton Rahman, et al.
Lancet (London, England)
|
September 30, 2014
Oncogenic osteomalacia presenting as a crippling illness in a young man
Melvin Khee-Shing Leow, Laniyati Hamijoyo, Huiling Liew, et al.
Journal of Drugs in Dermatology : JDD
|
August 4, 2012
Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial
Tsen-Fang Tsai, Michael Song, Yaung-Kaung Shen, et al.
Journal of Pain and Symptom Management
|
September 24, 2025
Bereavement Experiences Among Parents of Children With Spinal Muscular Atrophy Type 1
Christina M Mulé, Abigail Riley, Debra Lerner, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 70) with videos related to
Sort By:
Page
of 7
Annals of the Rheumatic Diseases
|
April 22, 2016
Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2)
Arthur Kavanaugh, Lluis Puig, Alice B Gottlieb, et al.
The Journal of Dermatology
|
October 22, 2019
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2
Kristian Reich, Michael Song, Shu Li, et al.
Arthritis Care & Research
|
August 3, 2016
Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis
Proton Rahman, Lluis Puig, Alice B Gottlieb, et al.
The Journal of Rheumatology
|
April 3, 2019
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials
Iain B McInnes, Lluís Puig, Alice B Gottlieb, et al.
The Journal of Investigative Dermatology
|
June 18, 2019
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study
Kenneth B Gordon, April W Armstrong, Peter Foley, et al.
Arthritis Care & Research
|
June 23, 2015
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial
Arthur Kavanaugh, Lluís Puig, Alice B Gottlieb, et al.
Annals of the Rheumatic Diseases
|
February 21, 2014
Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials
Arthur Kavanaugh, Christopher Ritchlin, Proton Rahman, et al.
Lancet (London, England)
|
September 30, 2014
Oncogenic osteomalacia presenting as a crippling illness in a young man
Melvin Khee-Shing Leow, Laniyati Hamijoyo, Huiling Liew, et al.
Journal of Drugs in Dermatology : JDD
|
August 4, 2012
Ustekinumab improves health-related quality of life in Korean and Taiwanese patients with moderate to severe psoriasis: results from the PEARL trial
Tsen-Fang Tsai, Michael Song, Yaung-Kaung Shen, et al.
Journal of Pain and Symptom Management
|
September 24, 2025
Bereavement Experiences Among Parents of Children With Spinal Muscular Atrophy Type 1
Christina M Mulé, Abigail Riley, Debra Lerner, et al.
Page
of 7